Vir Biotechnology Financials - Benzinga

Vir Biotechnology Inc

VIRNASDAQ

Trade with Public

Trade with Public

$9.61

0.121.26%

Dern. MÀJ: Aug 19, 12:03 PM

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

Vir Biotechnology Financials

Vir Biotechnology (VIR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate

Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.18 by 161.11 percent. This is a 158.75 percent increase over losses of $(0.80) per share from

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M YoY.

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.85) per share. This is a 3.41 percent increase over losses of $(0.88) per share from the same period last year. The company reported $(29.000 thousand) in

Benzinga Newsdesk

These Analysts Boost Their Forecasts On Vir Biotechnology

Avi Kapoor

Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED)

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the headline were updated in the story.) U.S. stock futures pared earlier gains and fluctuated on Tuesday after closing lower on Monday. Futures of all the major benchmark indices were mixed following a sell-off.

Rishabh Mishra

Vir Biotechnology Stock Hits 52-Week High Tuesday - Here's Why

Vir Biotechnology stock skyrockets after $335 million Astellas deal, strong prostate cancer data, and upbeat earnings boost outlook.

Vandana Singh

© 2026 Benzinga | All Rights Reserved